TY - JOUR T1 - The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient – a case study JF - medRxiv DO - 10.1101/2021.01.23.21249554 SP - 2021.01.23.21249554 AU - Chiara Sepulcri AU - Chiara Dentone AU - Malgorzata Mikulska AU - Bianca Bruzzone AU - Alessia Lai AU - Daniela Fenoglio AU - Federica Bozzano AU - Annalisa Bergna AU - Alessia Parodi AU - Tiziana Altosole AU - Emanuele Delfino AU - Giulia Bartalucci AU - Andrea Orsi AU - Antonio Di Biagio AU - Gianguglielmo Zehender AU - Filippo Ballerini AU - Stefano Bonora AU - Raffaele De Palma AU - Guido Silvestri AU - Andrea De Maria AU - Matteo Bassetti Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/26/2021.01.23.21249554.abstract N2 - Background Immunocompromised patients show prolonged shedding of SARS-CoV-2 in nasopharyngeal swabs. We report a case of a prolonged persistence of viable SARS-CoV-2 associated with clinical relapses of COVID-19 in a lymphoma patient.Methods Nasopharyngeal swabs and blood samples were tested for SARS-CoV-2 by Real time-PCR (RT-PCR). On five positive nasopharyngeal swabs, we performed viral culture and next generation sequencing. We analysed the patients’ adaptive and innate immunity to characterize T and NK cell subsets.Findings SARS-CoV-2 RT-PCR on nasopharyngeal swabs samples remained positive with cycle threshold mean values of 22 ± 1·3 for over 8 months. All five performed viral cultures were positive and genomic analysis confirmed a persistent infection with the same strain. Viremia resulted positive in three out of four COVID-19 clinical relapses and cleared each time after remdesivir treatment. T and NK cells dynamic was different in aviremic and viremic samples and no SARS-CoV-2 specific antibodies were detected throughout the disease course.Interpretation In our patient, SARS-CoV-2 persisted with proven infectivity for over eight months. Viremia was associated with COVID-19 relapses and remdesivir treatment was effective in viremia clearance and symptoms remission, although it was unable to clear the virus from the upper respiratory airways. During the viremic phase, we observed a low frequency of terminal effector CD8+ T lymphocytes in peripheral blood that are probably recruited in inflammatory tissue for viral eradication. In addition we found a high level of NK cells repertoire perturbation with a relevant involvement during SARS-CoV-2 viremia.Funding None.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was carried out in accordance with the principles of the Declaration of Helsinki and approved by the Ethic Committee of Liguria Region (Comitato Etico Regione Liguria) (N. CER Liguria 114/2020 - ID 10420).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and supplementary material. ER -